外阴与阴道癌的综合管理
本文综述外阴癌与阴道癌的病因、组织病理学及治疗策略。外阴癌手术切除加腹股沟股淋巴结分期是主要治疗手段,局部晚期者当需行脏器切除术时建议放化疗;复发或转移性疾病全身治疗有限,5年生存率约20%。强烈提倡参加临床试验并及早获得最佳支持治疗。
要点
- 外阴癌手术切除加腹股沟股淋巴结分期是主要治疗手段。
- 局部晚期外阴癌当需行脏器切除术时建议放化疗。
- 复发或转移性疾病全身治疗有限,5年生存率约20%,强烈提倡参加临床试验。
核心结论
- 外阴癌与阴道癌为罕见恶性肿瘤,当前证据主要来自回顾性研究或小型2期试验或从宫颈癌治疗外推,强烈提倡参加临床试验并及早获得最佳支持治疗以减轻局部区域进展对生活质量的影响。
研究设计与样本
- 本文为综述,阐述外阴与阴道癌及外阴阴道黑色素瘤和肉瘤的病因、组织病理学与治疗策略。
- 外阴癌发病率为每10万女性2.7例,主要影响60岁以上女性,但年轻人群发病率呈上升趋势。
- 约90%外阴癌为鳞状细胞癌,常与人乳头瘤病毒(HPV)感染相关;阴道癌占所有女性癌症不足1%,同样呈HPV相关趋势。
主要发现
- 外阴癌诊断后2年内复发率为12%至37%。
- 复发或转移性疾病全身治疗有限,5年生存率约20%。
- 未来HPV疫苗接种举措可能降低癌症发病率,但其显著效果需数十年才能显现。
关键数值与推荐
- 外阴癌手术干预包括肿瘤切除和腹股沟股淋巴结分期。
- 局部晚期外阴癌当需行脏器切除术时建议放化疗。
- 强烈提倡参加临床试验,并及早获得最佳支持治疗。
临床怎么用
- 外阴癌以手术切除加腹股沟股淋巴结分期为主要治疗方式。
- 局部晚期外阴癌当需行脏器切除术时建议放化疗。
- 复发或转移性疾病全身治疗有限,强烈提倡参加临床试验并及早获得最佳支持治疗。
- 需仔细考虑治疗对体像和性功能的社会心理影响。
局限性
- 当前证据主要来自回顾性研究或小型2期试验,或从宫颈癌治疗外推。
- HPV疫苗接种的显著效果需数十年才能显现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vulvar and vaginal cancers represent rare malignancies, with an incidence of 2.7 per 100,000 women for vulvar cancer, predominantly affecting women older than 60 years, although rising rates are observed in younger demographics. Approximately 90% of vulvar cancers are squamous cell carcinoma and frequently are associated with human papillomavirus (HPV) infection. Vaginal cancer, constituting less than 1% of all female cancers, similarly exhibit HPV-related trends. This review delineates the etiology, histopathology, and treatment strategies for carcinomas and vulvovaginal melanomas and sarcomas. Surgical intervention remains the primary treatment modality for vulvar cancer, involving tumor resection and inguinofemoral lymph node staging. For locally advanced vulvar carcinoma, chemoradiation is advised when exenterative surgery would be indicated. Recurrence rates within 2 years after diagnosis range from 12% to 37%. Unfortunately, systemic treatments for recurrent or metastatic disease are limited, with 5-year survival rates at approximately 20%. Current evidence primarily derives from retrospective studies or small phase 2 trials or otherwise is extrapolated from the treatment of cervical cancer. Enrollment in clinical trials is strongly advocated, along with prompt access to best supportive care to mitigate the effect of locoregional progression on quality of life. Moreover, the psychosocial implications of treatment on body image and sexuality necessitate careful consideration. Future HPV vaccination initiatives may reduce cancer incidence, although significant effects of such vaccination will manifest over decades, underscoring the urgent need to enhance treatment efficacy and minimize morbidity in vulvar and vaginal cancers.
引用
- Nogueira-Rodrigues A, Oonk MHM, Lorusso D, et al. Comprehensive management of vulvovaginal cancers. CA Cancer J Clin. 2025. PMID: 40377134. doi:10.3322/caac.70014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。